Regeneron's Earnings Took A Big Tax Hit, And Still Pounded ForecastsInvestors Business Daily • 10/28/25
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?Zacks Investment Research • 10/24/25
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPSZacks Investment Research • 10/23/25
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to DeclineZacks Investment Research • 10/21/25
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and RadiationGlobeNewsWire • 10/17/25
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)Zacks Investment Research • 10/16/25
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat CancersGlobeNewsWire • 10/15/25
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing LossZacks Investment Research • 10/13/25
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing LossGlobeNewsWire • 10/12/25
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug LibtayoZacks Investment Research • 10/09/25
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and RadiationGlobeNewsWire • 10/08/25
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025GlobeNewsWire • 09/30/25